Thursday, May 2, 2024
Home All News Stand Down. Page 3

Stand Down.

    We get paid to be suspicious when we’ve got nothing to be suspicious about.

    Featured posts
    Internet Stock Review

    Immunomedics (IMMU) up 100% Today or $2 Billion in Value & Stand Down VIII:

    Stand Down. Editor / Curator -
    Bear Comments from Roubini, Jim Chanos, Jim Rogers and James A. Kostohryz Don't Be That Guy in Denial!

    Stand Down VII: Could We Have a Down 20% Day?

    Stand Down. Editor / Curator -
    Be Careful of Mondays. stand down: phrasal verb of stand 1. relax or cause to relax after a state of...

    Stand Down VI: Dow 10,000? It Could Happen.

    Biotech News Editor / Curator -
    WILL FALLING RATES SAVE THE DAY? And yet, we're not worried. While we're not predicting it,...

    Stand Down IV: Remember This? Alta Vista Cancels IPO. David Wetherell Takes a $2...

    Stand Down. Editor / Curator -
    We are going through some of our very old 'incubator files' back from when we ran the Incubator Stock Review, a spinoff...

    Stand Down III: Guess Who This Beautiful Chart Belongs to?

    Stand Down. Editor / Curator -
    Answer Below.. $14 to $593. That's $140,000 to $5,930,000. That's Real Money.
    123Page 3 of 3

    Latest article

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.